Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain

Background: Baricitinib is an oral janus kinase inhibitor for the treatment of rheumatoid arthritis (RA) and is approved in Europe for use in adults with moderately-to-severely active RA and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drug (csDMARD...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlueter, Max, Finn, Elaine, Díaz, Silvia, Dilla, Tatiana, Inciarte-Mundo, José, Fakhouri, Walid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560251/
https://www.ncbi.nlm.nih.gov/pubmed/31239736
http://dx.doi.org/10.2147/CEOR.S201621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560251/
https://www.ncbi.nlm.nih.gov/pubmed/31239736
http://dx.doi.org/10.2147/CEOR.S201621

Ejemplares similares